Alvotech to Join the Morgan Stanley Global Healthcare Conference
Alvotech (NASDAQ: ALVO), a leading biotech firm focused on developing and manufacturing biosimilar medicines for patients around the globe, is excited to announce its participation in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference. This important event will feature a fireside chat with members of Alvotech's management team.
Event Details
The in-person fireside chat is set to begin at 5:35 PM EDT. Attendees will have a chance to interact with Alvotech's leadership and gain valuable insights into the company's strategic direction and advancements in the biosimilar industry.
Live Audio Webcast and Recording
For those who cannot attend the conference in person, Alvotech will offer a live audio webcast of the session. This webcast will be available during and after the event on Alvotech’s investor website. Furthermore, a recording will be archived and accessible for at least 90 days, providing stakeholders with ample opportunity to catch up on the discussions.
About Alvotech
Founded by Robert Wessman, Alvotech is dedicated solely to the development and production of biosimilar medicines, with the goal of enhancing patient access to affordable treatments worldwide. The company strives to lead the biosimilar market by delivering high-quality products supported by comprehensive in-house capabilities.
Recent Developments
To date, Alvotech has successfully launched two biosimilars and maintains a strong development pipeline that includes nine disclosed biosimilar candidates. These candidates are aimed at addressing a variety of medical conditions, such as autoimmune disorders, respiratory diseases, osteoporosis, eye disorders, and cancer.
Strategic Partnerships
In order to broaden its market presence, Alvotech has formed a strategic network of commercial partnerships across several continents. Collaborations with major pharmaceutical companies like Teva Pharmaceuticals, STADA Arzneimittel AG, and Fuji Pharma Co., Ltd. enhance Alvotech’s capability to deliver its innovative solutions in diverse global markets, including the United States, Europe, and various regions in Asia and South America.
Company Vision
Alvotech's vision centers on providing high-quality, cost-effective biosimilar products and services. With a commitment to comprehensive patient care, the company is focused on advancing therapeutic options and improving health outcomes through its reliable biosimilar healthcare solutions.
Engagement with Investors
Investors and interested parties are encouraged to visit Alvotech’s investor portal for further information. The company's website also offers a wealth of resources regarding its facilities, product pipelines, and strategic initiatives.
Frequently Asked Questions
What is the focus of Alvotech?
Alvotech specializes in developing and manufacturing biosimilar medicines aimed at providing affordable treatment options for patients worldwide.
When will Alvotech’s fireside chat take place?
The fireside chat is scheduled to start at 5:35 PM EDT during the Morgan Stanley Global Healthcare Conference.
How can I access the live webcast of the event?
The live audio webcast can be accessed on the events section of Alvotech’s investor website during and after the conference.
What biosimilar categories is Alvotech developing?
Alvotech is developing biosimilar candidates that focus on various conditions, including autoimmune disorders, cancer, and respiratory diseases.
How long will the recording of the event be available?
The recording will be archived and available for at least 90 days following the event.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
